Peter Sportelli

Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study

Howard A. Burris, Ian W. Flinn, Manish R. Patel et al. · The Lancet Oncology · 2018 · 205 citations

Medicine, Oncology, Pharmacology +16

Dual Inhibition of Akt/Mammalian Target of Rapamycin Pathway by <i>Nanoparticle Albumin-Bound</i> –Rapamycin and Perifosine Induces Antitumor Activity in Multiple Myeloma

Diana Cirstea, Teru Hideshima, Scott J. Rodig et al. · Molecular Cancer Therapeutics · 2010 · 166 citations · Full text

Medicine, Oncology, Pharmacology +14

Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma

Nathan Fowler, Felipe Samaniego, Wojciech Jurczak et al. · Journal of Clinical Oncology · 2021 · 161 citations · Full text

Medicine, Oncology, Pharmacology +13

Perifosine Plus Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Bortezomib: Results of a Multicenter Phase I/II Trial

Paul G. Richardson, J. Wolf, Andrzej Jakubowiak et al. · Journal of Clinical Oncology · 2011 · 119 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1–1b study

Matthew S. Davids, Haesook T. Kim, Alyssa Nicotra et al. · The Lancet Haematology · 2018 · 115 citations · Full text

Medicine, Oncology, Pharmacotherapy +15